share_log

Kaskela Law LLC Announces Investigation of EFFECTOR Therapeutics, Inc. (EFTR) and Encourages Former EFFECTOR Employees to Contact the Firm

Kaskela Law LLC Announces Investigation of EFFECTOR Therapeutics, Inc. (EFTR) and Encourages Former EFFECTOR Employees to Contact the Firm

Kaskela Law LLC宣佈調查EFFECTOR Therapeutics,Inc.(EFTR),鼓勵以前的EFFECTOR員工聯繫該公司
newsfile ·  07/15 20:00

Philadelphia, Pennsylvania--(Newsfile Corp. - July 15, 2024) - Kaskela Law LLC announces that it is investigating eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) on behalf of the company's former employees.

Kaskela法律公司宣佈,正在代表公司前員工調查eFFECTOR Therapeutics Inc. (NASDAQ: EFTR)

On August 25, 2021, Locust Walk Acquisition Corp. ("Locust Walk"), a publicly traded special purpose acquisition ("SPAC") company, announced that Locust Walk's stockholders had approved of an acquisition of privately held eFFECTOR Therapeutics ("Legacy eFFECTOR"). Locust Walk also announced that, upon the closing of the acquisition, the combined company would be renamed eFFECTOR Therapeutics, Inc. and its common stock would start trading under ticker symbol NASDAQ: EFTR.

2021年8月25日,公開交易的特殊目的收購公司Locust Walk Acquisition Corp. ("Locust Walk")宣佈,Locust Walk的股東已批准收購私人擁有的Legacy eFFECTOR。Locust Walk還宣佈,收購完成後,合併後的公司將更名爲eFFECTOR Therapeutics,股票將在逐筆明細(NASDAQ: EFTR)下開始交易。

In connection with the closing of the acquisition, many of Legacy eFFECTOR's executives and employees had their previously held shares/stock options of privately held Legacy eFFECTOR converted into shares of publicly traded eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR). The investigation seeks to determine whether this share conversion was done in a fair manner and in accordance with the securities laws, or whether former Legacy eFFECTOR shareholders were financially harmed in connection with the conversion.

與收購的完成相關聯的是,Legacy eFFECTOR的許多高管和員工將其之前持有的私有Legacy eFFECTOR的股票/期權換成了公開交易的eFFECTOR Therapeutics,Inc.(NASDAQ: EFTR)的股票。該調查旨在確定這種股票轉換是否公平並符合證券法規定,或者在股票轉換中前Legacy eFFECTOR股東是否受到了經濟損失。

Former Legacy eFFECTOR employees who had their shares/stock options of privately held Legacy eFFECTOR converted into publicly traded shares of eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional information about this investigation and their legal rights and options at (484) 229 - 0750 or (888) 715 - 1740, or by clicking on the following link (or if necessary, by copying and pasting the link into your browser):

鼓勵之前持有Legacy eFFECTOR的股票/期權並轉換爲公開交易的eFFECTOR Therapeutics Inc. (NASDAQ: EFTR)股票的前Legacy eFFECTOR員工聯絡Kaskela Law LLC (D. Seamus Kaskela, Esq. 或 Adrienne Bell, Esq.)以獲取有關調查的更多信息及其法律權利和期權,電話:(484) 229-0750 或 (888) 715-1740,或單擊以下鏈接(如果必要,複製並粘貼鏈接到您的瀏覽器中):

Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about Kaskela Law LLC please visit .

Kaskela Law LLC專門代表投資者參與詐騙,公司治理和合並併購訴訟,以不定期基礎。有關Kaskela Law LLC的其他信息,請訪問。

CONTACT:
KASKELA LAW LLC
D. Seamus Kaskela, Esq.
(skaskela@kaskelalaw.com)
Adrienne Bell, Esq.
(abell@kaskelalaw.com)
18 Campus Blvd., Suite 100
Newtown Square, PA 19073
(888) 715 - 1740
(484) 229 - 0750

聯繫人:
KASKELA LAW LLC
D. Seamus Kaskela,Esq。
(skaskela@kaskelalaw.com)
Adrienne Bell,Esq。
(abell@kaskelalaw.com)
18 Campus Blvd.,Suite 100
Newtown Square,PA 19073
(888)715-1740
(484)229-0750

This notice may constitute attorney advertising in certain jurisdictions.

在某些司法管轄區,此通知可能構成律師廣告。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論